Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genaera Evizon macular degeneration SPA

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Genaera plans to begin two identical pivotal trials of Evizon (squalamine) "in the very near future" following a special protocol assessment agreement with FDA, the firm says June 27. The trials will enroll patients with predominantly classic, minimally classic and occult forms of wet age-related macular degeneration. The primary endpoint will be visual acuity at one year; maintenance dosing will continue through two years. Genaera has three Phase II trials of Evizon ongoing. FDA selected the anti-angiogenic agent for its continuous marketing application Pilot 2 program earlier this year; the program provides frequent feedback and interaction with the agency during the IND phase of development (1Pharmaceutical Approvals Monthly January 2005, In Brief)...

You may also be interested in...



Squalamine selected for Pilot 2

FDA taps Genaera's anti-angiogenic squalamine for its Continuous Marketing Application Pilot 2 program, the firm announces Jan. 4. Squalamine was selected by CDER's Division of Anti-Inflammatory, Analgesic and Ophthalmic Drug Products; the program provides frequent scientific feedback and interaction during the IND phase, with each review division choosing one participant. Squalamine is being developed for "wet" age-related macular degeneration. Phase II trials are underway, with data expected in the first quarter. Genaera plans to begin Phase III in the first half of 2005, to run concurrently with its largest Phase II study...

Vaccination Health Next Stop For Dentovations’ Self+ Immunity Supplement Line

Vacci Prep is first “supplement to establish a standard of care for consumers when preparing their immune system for vaccinations,” Dentovations says.

Balancing Innovation And Safety – The US and Australian Medtech Regulatory Systems Compared

Effective medical device regulation supports both safety and innovation needs. This article assesses how well the US FDA and the Australian TGA achieve this balance.

Topics

UsernamePublicRestriction

Register

ID1132298

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel